When is ER and PgR testing indicated in patients with breast tumors?

Updated: Mar 20, 2019
  • Author: Oudai Hassan, MD; Chief Editor: Chandandeep Nagi, MD  more...
  • Print


The result of estrogen receptor (ER) and progesterone receptor (PgR) testing is used to identify patients who are most likely to benefit from endocrine therapy (tamoxifen, ovarian ablation, aromatase inhibitors, irreversible ER inhibitors). ER and PgR should be measured in every primary invasive breast cancer, and they may be measured on metastatic lesions if the results would influence treatment planning. In both premenopausal and postmenopausal patients, steroid hormone receptor status should be used to identify patients who are the most likely to benefit from endocrine forms of therapy in the settings of early breast cancer and metastatic disease. In patients with ductal carcinoma in situ (DCIS) who are candidates for hormonal therapy, the data are insufficient to recommend routine measurement of ER and PgR for therapeutic guidance. [1]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!